Site Sponsors
  • Oxford Instruments Nanoanalysis - X-Max Large Area Analytical EDS SDD
  • Strem Chemicals - Nanomaterials for R&D
  • Park Systems - Manufacturer of a complete range of AFM solutions
Posted in | Nanomedicine

There is 1 related live offer.

Save 25% on magneTherm

SDSU’s Novel Nanoparticle Vaccine Study to be Unveiled at AAPS NBC

Published on May 22, 2013 at 7:04 AM

A novel vaccine study from South Dakota State University (SDSU) will headline the groundbreaking research that will be unveiled at the American Association of Pharmaceutical Scientists’ (AAPS) National Biotechnology Conference (NBC). The meeting takes place Monday, May 20 - Wednesday, May 22 at the Sheraton San Diego Hotel and Marina.

“The main goal of a vaccine is to stimulate the immune system to fight against a pathogen that causes the disease”, explained Dr. Hemachand Tummala, assistant professor of Pharmaceutical Sciences at SDSU. "We want to make a delivery system that mimics pathogens in stimulating the immune system but not cause infection."

Tummala and his doctoral student, Sunny Kumar, used inulin acetate taken from a fiber derived from tubers, such as dahlias or chicory. “The fiber is natural, inexpensive and easily accessible”, Tummala stated. “Most importantly, it acts as a PAMP [pathogen-associated molecular pattern]. We made pathogen-like nanoparticles with inulin acetate and incorporated pathogen-related antigens inside them.” Tummala explained, "Once the antigen presenting cells sense these particles as pathogens, they eat them and process them as PAMPs." This then aggravates the immune system.

The researchers then tested the technology in preventing a viral disease. Tummala collaborated with Dr. Victor Huber, assistant professor and infectious disease specialist at the Sanford School of Medicine, whose research focuses on influenza.

The researchers then tested the efficiency of the vaccine delivery system in mice against a lethal challenge of the 2009 pandemic H1N1 flu virus. One group of mice was not immunized, while the others received a vaccine containing one or two antigens. Within eight days, 90 percent of the unvaccinated mice died. Those who received one antigen contracted the flu, and all but one recuperated. None of those who received the vaccine with two antigens acquired the flu.

“The low cost of the technology, estimated at one or two dollars per dose, also makes it suitable for animal vaccines,” Tummala explained. He is working with other SDSU researchers to apply the delivery to sheep and swine vaccines.

Dr. Tummala and his team will also receive the 2013 American Association of Pharmaceutical Scientists Innovation in Biotechnology Award for their research on Tuesday, May 21.

Source: http://www.aaps.org/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit